In a re­peat set­back, Neu­ro­crine flags a fail­ure for Tourette syn­drome study — shares sink

Shares of Neu­ro­crine $NBIX got ham­mered Tues­day morn­ing af­ter the biotech con­ced­ed that its Phase IIb study of val­be­nazine for Tourette syn­drome had flopped.

The stock swift­ly plunged more than 20% on the news.

The pri­ma­ry end­point for their study was a re­duc­tion in fa­cial tics among pa­tients with the dis­ease. We’re not get­ting to see the ac­tu­al da­ta yet to see just how bad a set­back this is.

Kevin Gor­man, CEO Get­ty

Click on the im­age to see the full-sized ver­sion

Neu­ro­crine has had plen­ty of prob­lems to deal with in this field. Their drug failed an ear­li­er study for Tourette syn­drome in the spring of 2017, spurring ex­ecs to vow they would come back with a bet­ter study de­sign that would in­clude bet­ter dos­ing.

But that didn’t play out well.

The FDA ap­proved In­grez­za (val­be­nazine) for tar­dive dysk­i­ne­sia in April, 2017, their first ever reg­u­la­to­ry OK. Then soon af­ter its part­ner Ab­b­Vie came through with promis­ing late-stage da­ta for their en­dometrio­sis drug elagolix, now on the mar­ket as Orilis­sa, which the biotech had out­li­censed to them in 2010.

Re­peat fail­ure in hand, they’ll be study­ing next steps re­gard­ing this drug’s fu­ture in Tourette syn­drome — if it has one.

Stifel’s Paul Mat­teis had some apol­o­giz­ing to do af­ter the news hit.

(W)e were wrong to have been op­ti­mistic here as we had mod­eled a 75% prob­a­bil­i­ty-of-suc­cess. The press re­lease lacks da­ta, but it does trans­par­ent­ly con­vey that, (1) treat­ment-re­lat­ed ad­verse events were con­sis­tent with oth­er stud­ies, (2) place­bo per­formed as ex­pect­ed, but (3) the drug ef­fect was small­er than man­age­ment had an­tic­i­pat­ed. There­fore, it seems like­ly that the an­nounce­ment will lead in­vestors to re­move TS from the mod­el.

And Baird’s Bri­an Sko­r­ney went back to do some math on his peak sales es­ti­mates, shav­ing off close to a bil­lion dol­lars.

(W)e are re­duc­ing our peak sales es­ti­mate for In­grez­za from $2.09B to $1.17B to ac­count for the re­moval of the Tourette mar­ket op­por­tu­ni­ty.

“We are very dis­ap­point­ed with the top-line da­ta from the T-Force GOLD study giv­en that chil­dren and ado­les­cents with Tourette syn­drome need bet­ter treat­ment op­tions. This study was well-con­duct­ed with a place­bo re­sponse as ex­pect­ed, but the treat­ment ef­fect of val­be­nazine was low­er than we had an­tic­i­pat­ed,” said Neu­ro­crine CEO Kevin Gor­man in a pre­pared state­ment.

Tower Bridge in London [Shutterstock]

#UK­BIO19: Join GSK’s Hal Bar­ron and a group of top biotech ex­ecs for our 2nd an­nu­al biotech sum­mit in Lon­don

Over the past 10 years I’ve made a point of getting to know the Golden Triangle and the special role the UK biopharma industry plays there in drug development. The concentration of world class research institutes, some of the most accomplished scientists I’ve ever seen at work and a rising tide of global investment cash leaves an impression that there’s much, much more to come as biotech hubs are birthed and nurtured.

Deborah Dunsire. Lundbeck

UP­DAT­ED: Deb­o­rah Dun­sire is pay­ing $2B for a chance to leap di­rect­ly in­to a block­buster show­down with a few of the world's biggest phar­ma gi­ants

A year after taking the reins as CEO of Lundbeck, Deborah Dunsire is making a bold bid to beef up the Danish biotech’s portfolio of drugs in what will likely be a direct leap into an intense rivalry with a group of giants now carving up a growing market for new migraine drugs.

Bright and early European time Monday morning the company announced that it will pay up to about $2 billion to buy Alder, a little biotech that is far along the path in developing a quarterly IV formulation of a CGRP drug aimed at cutting back the number of crippling migraines patients experience each month. In a followup call, Dunsire also noted that the company will likely need 200 to 250 reps for this marketing task on both sides of the Atlantic. And analysts were quick to note that the dealmaking at Lundbeck isn’t done, with another $2 billion to $3 billion available for more deals to beef up the pipeline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,400+ biopharma pros reading Endpoints daily — and it's free.

It’s fi­nal­ly over: Bio­gen, Ei­sai scrap big Alzheimer’s PhI­I­Is af­ter a pre­dictable BACE cat­a­stro­phe rais­es safe­ty fears

Months after analysts and investors called on Biogen and Eisai to scrap their BACE drug for Alzheimer’s and move on in the wake of a string of late-stage failures and rising safety fears, the partners have called it quits. And they said they were dropping the drug — elenbecestat — after the independent monitoring board raised concerns about…safety.

We don’t know exactly what researchers found in this latest catastrophe, but the companies noted in their release that investigators had determined that the drug was flunking the risk/benefit analysis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,400+ biopharma pros reading Endpoints daily — and it's free.

Scott Gottlieb, AP Images

Scott Got­tlieb has a new board po­si­tion to add to the re­sume — and this one is fo­cused on a fa­vorite sub­ject

Scott Gottlieb has another position to add to his lengthy roster of boards and advisory roles in the wake of his departure from the helm of the FDA.

He’ll be joining the advisory board of FasterCures, a think tank which former junk bond king Michael Milken set up to help drive more drugs to the market, looking to accelerate drug R&D. That’s a subject close to the heart of Gottlieb, who blazed a trail at the FDA focused on hustling up the process. That helped endear him to the industry, making him one of the most popular commissioners in FDA history.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,400+ biopharma pros reading Endpoints daily — and it's free.

Karyopharm lines up $150 mil­lion cash in­jec­tion to back con­tro­ver­sial drug launch

Karyopharm has entered into a royalty agreement worth up to $150 million to back the launch of their multiple myeloma drug — recently approved by the FDA over the objections of a majority of the agency’s outside experts.

The deal with HealthCare Royalty Partners, worth $75 million now and $75 million once certain regulatory and commercial milestones have been reached, will fund the commercialization of Karyopharm’s oral SINE compound Xpovio (selinexor) for patients with multiple myeloma who have already had at least four prior therapies. The money will help Karyopharm as it markets its newly approved drug and pushes through clinical trials testing the drug on refractory multiple myeloma patients with one to three therapies and patients with treatment-resistant diffuse large B-cell lymphoma. It will give Karyopharm a cushion through mid-2021.

Af­ter a run of CT­LA-4 com­bo fail­ures, sci­en­tists spot­light a way to make it work — in se­lect pa­tients

CTLA-4/PD-(L)1 combinations have been one of the El Dorados of oncology, its promise forever behind that next hill but apparently unattainable after a series of pivotal clinical failures. But researchers at New York’s Memorial Sloan Kettering Cancer Center and the Technical University of Munich think they may know how to fix what’s wrong and boost the drive to next-gen cancer combos.

In a preclinical animal research program, researchers found that within a cell, checkpoints rely on a specific molecule — RNA-sensing molecule RIG-I — to work. If that sounds familiar, it’s because it has already been identified as a target for boosting immune responses and was subject to at least one Phase I/II trial. Pfizer in December allied itself with Kineta with $15 million upfront and $505 million in potential milestones to develop RIG-I immunotherapies, and three years ago Merck purchased German upstart Rigontec for $137 million upfront and over $400 million in potential milestones for the same purpose.

Pur­due Phar­ma files for bank­rupt­cy as first step in $10B opi­oid set­tle­ment

It’s settled. Purdue Pharma has filed for bankruptcy as part of a deal that would see the OxyContin maker hand over $10 billion in cash and other contributions to mitigate the opioid crisis — without acknowledging any wrongdoing in the protracted epidemic that’s resulted in hundreds of thousands of deaths.

The announcement came two weeks after news of a proposed settlement surfaced and largely confirm what’s already been reported.

Lisa M. DeAngelis, MSKCC

MSK picks brain can­cer ex­pert Lisa DeAn­ge­lis as its next CMO — fol­low­ing José Basel­ga’s con­tro­ver­sial ex­it

It’s official. Memorial Sloan Kettering has picked a brain cancer expert as its new physician-in-chief and CMO, replacing José Baselga, who left under a cloud after being singled out by The New York Times and ProPublica for failing to properly air his lucrative industry ties.

His replacement, who now will be in charge of MSK’s cutting-edge research work as well as the cancer care delivered by hundreds of practitioners, is Lisa M. DeAngelis. DeAngelis had been chair of the neurology department and co-founder of MSK’s brain tumor center and was moved in to the acting CMO role in the wake of Baselga’s departure.

Penn team adapts CAR-T tech, reengi­neer­ing mouse cells to treat car­diac fi­bro­sis

After establishing itself as one of the pioneer research centers in the world for CAR-T cancer therapies, creating new attack vehicles to eradicate cancer cells, a team at Penn Medicine has begun the tricky transition of using the basic technology for heart repair work.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,400+ biopharma pros reading Endpoints daily — and it's free.